The central government is expecting a positive outcome from its final round of three-dose talks with Zydus Cadila. Covid-19 Vaccine ZyCov-D For children, Karnataka Health Minister K Sudhakar was quoted as saying by the news agency PTI.
After meeting with Mansukh Mandaviya in Delhi, Sudhakar said, “I had a long discussion with the Union Health Minister regarding vaccination for children.”
“He informed that the government is in the final round of discussions with Zydus regarding the COVID-19 vaccine for children and added that he is expecting positive results soon,” the minister said.
In addition, Sudhakar said that he also discussed the status of the nasal vaccine with Bharat Biotech’s chairman and managing director Krishna Ella, who was present at the meeting.
He said the second clinical trial of the nasal vaccine developed by Bharat Biotech has been completed and the third is expected by November-December.
Sudhakar said, “It was informed that the second clinical trial of this vaccine has been completed and the third clinical trial will be over by the end of November-December.” Ella said that the company has the capacity to manufacture 200 million doses. Vaccine one month.
Zydus Covid Vaccine Price
Indian drugmaker Zydus Cadila has proposed its ZyCov-D at the price of ₹1,900, reported PTI, quoting sources. However, the news agency said that the central government is in talks with the firm to reduce the rates.
“Talks are on. The company has been asked to reconsider all aspects regarding the cost of the vaccine.”
Another source said ZyCoV-D should be priced differently than Covaxin and CoviSheeld because, in addition to being a three-dose vaccine, a needle-free jet injector is used to administer the vaccine. , which has a price. ₹30,000.
That jet injector can be used to deliver about 20,000 doses.
About three rounds of meetings have been held between the Center and the company so far.
vaccination for children
Meanwhile, the Union Health Ministry is also considering the recommendations of the National Technical Advisory Group on Immunization (NTAGI) for introducing ZyCoV-D in the vaccination campaign and giving priority to the beneficiaries who are in the age group of 12-18 years with comorbidities. is waiting.
An official source said that NTAGI will provide the protocol and framework to include this vaccine in the Kovid-19 vaccination campaign.
Don’t miss a story! Stay connected and informed with Mint.
download
Our App Now!!
.